LOUIS, Feb. 23, 2017-- Stereotaxis, Inc., a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Takatsuki General Hospital, a leading acute care ...
- GlobeNewswire•8 days ago
LOUIS, Feb. 16, 2017-- Stereotaxis, Inc., a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, and the Montreal Heart Institute, an internationally recognized research ...
- American City Business Journals•18 days ago
William C. Mills III has resigned as CEO of Stereotaxis, the St. Louis-based medical device maker that operates out of the Cortex innovation district. Mills also resigned his board seat at the company, which develops medical devices for treating cardiac arrhythmias. David Fischel has been named acting CEO and chairman of the board, effective immediately.
STXS : Summary for STEREOTAXIS INC COM USD0.001 - Yahoo Finance
Stereotaxis, Inc. (STXS)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.61 - 0.63|
|52 Week Range||0.47 - 1.95|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.71|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|